Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07135427 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

Study acronym: IgG in AATD
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2025 to Sep 3, 2025 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Sep 2025 to Sep 3, 2025
    • Site details revised
  2. Study arms: 2 to 1v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.
Trial Details
NCT Number NCT07135427
Lead Sponsor University of Alabama at Birmingham
Collaborators: Alpha-1 Foundation
Conditions Alpha 1-Antitrypsin, COPD, Antibody Deficiency
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov